Please login to the form below

Not currently logged in
Email:
Password:

capmatinib

This page shows the latest capmatinib news and features for those working in and with pharma, biotech and healthcare.

Merck gets first approval for MET inhibitor tepotinib in Japan

Merck gets first approval for MET inhibitor tepotinib in Japan

Merck’s closest rival in the MET-positive lung cancer race is Novartis, whose capmatinib started a priority review in the US last month based on the results of the phase ... That showed an overall response rate with capmatinib of 68% with the drug

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics